Professor Paul Waring is an MD, PhD molecular pathologist and Fellow of the Royal College of Pathologists of Australasia, Fellow of the Royal College of Pathologists (UK) and Fellow of the Human Genetics Society of Australasia. He has held several senior positions in the pharmaceutical (Executive Director of Translational Pathology at Astrazeneca Cambridge UK, Senior Director of Pathology and Diagnostics, Genentech San Francisco USA) and diagnostic (Vice President Medical Innovation, Roche, Tucson USA) industries and in academia (Chair of Pathology, University of Melbourne, Australia) and clinical practice (Director of Pathology, Peter MacCallum Cancer Centre, Lifestrands Genomics and MyDNA in Melbourne and the Australian Translational Genome Centre in Brisbane).  He has over 20 years’ experience developing tissue based and genetic biomarkers and image analysis solutions ranging from pre-clinical studies to registrational clinical trials for over 80 pharmacodynamic and predictive biomarker programs. Notable highlights include initiating the ASCO/CAP HER2 testing guidelines and leading the strategic partnerships between Ventana Medical Systems and Genentech and Astrazeneca to co-develop Companion Diagnostic tests.